Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert J. Fram is active.

Publication


Featured researches published by Robert J. Fram.


Cancer | 1994

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study

Donna J. Glover; Alan Lipton; Alan Keller; Antonius A. Miller; Scott M. Browning; Robert J. Fram; Sebastian George; Kenneth Zelenakas; Richard S. Macerata; John J. Seaman

Background. Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose‐ranging trial.


Mutation Research\/dna Repair Reports | 1986

Mutagenesis and repair of DNA damage caused by nitrogen mustard, N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU), streptozotocin, and mitomycin C in E. coli

Robert J. Fram; J. Sullivan; Martin G. Marinus

Cytotoxicity and mutagenesis by streptozotocin, BCNU, nitrogen mustard, and mitomycin C were evaluated in E. coli mutants deficient in SOS repair, SOS-mediated mutagenesis, the adaptive response, and mutants that engage in aberrant mismatch repair. The results demonstrate that premutagenic lesions are caused by nitrogen mustard, BCNU and streptozotocin that are not repaired by ada or recognized by umuDC. Further, recA mutants were hypomutable after exposure to nitrogen mustard, BCNU, and streptozotocin compared to wild type. With the exception of the monofunctional nitrosourea, streptozotocin, both recA and uvrA gene products contribute to the repair of DNA damage caused by the alkylating agents tested. In the case of streptozotocin, although recA mutants were more sensitive than wild type, uvrA mutants were not. Moreover, while ada and alkA E. coli mutants showed increased sensitivity to streptozotocin, they were not more sensitive to the other alkylating agents evaluated.


Mutation Research Letters | 1986

Studies on mutagenesis and repair induced by platinum analogs

Robert J. Fram; Paul S. Cusick; Martin G. Marinus

Mutagenesis and cytotoxicity were studied in Escherichia coli by iproplatin and carboplatin, two analogs of cisplatin (CDDP) currently undergoing clinical trial. As with CDDP, mutagenesis by these agents was mediated by the umuDC gene product. In contrast to CDDP, however, mismatch repair did not substantially contribute to survival of cells after exposure to these agents since dam-3 E. coli were not more sensitive than wild type E. coli. UvrA- E. coli, however were more sensitive to these analogs demonstrating that as with CDDP, uvr endonuclease-mediated excision contributes to the repair of DNA damage induced by platinum compounds.


Biochemical Pharmacology | 1987

Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells☆

Norman Robichaud; Robert J. Fram

The present study was undertaken to determine whether cytotoxicity by 1-beta-D-arabinofuranosylcytosine (ara-C) in LoVo colon carcinoma cells, which are resistant to high concentrations of ara-C, would be enhanced by concurrent exposure to hydroxyurea (HU). Since mechanisms underlying the effects of HU on ara-C induced cytotoxicity are unclear, we also evaluated the effect of HU on the incorporation of ara-C into DNA, as well as potential consequences of misincorporation. Our results demonstrate that HU synergistically enhances cytotoxicity by ara-C in these cells. This effect was not present when HU was combined with aphidicolin, an agent that resembles ara-C in competing with dCTP for binding to polymerase alpha but that is not incorporated into DNA. Further, cells exposed to HU and ara-C incorporated up to 5-fold as much ara-C into DNA as cells solely treated with ara-C. While the extent of inhibition of DNA synthesis was comparable with cells exposed to HU and aphidicolin as those treated with HU and ara-C, recovery of DNA synthesis was delayed more significantly by the latter combination. These findings suggest that HU synergistically potentiates ara-C induced cytotoxicity by enhancing incorporation of ara-C in LoVo cell DNA.


Mutation Research | 1989

DNA repair mechanisms affecting cytotoxicity by streptozotocin in E. coli.

Robert J. Fram; S.L. Mack; M. George; Martin G. Marinus

Mechanisms underlying cytotoxicity by the monofunctional nitrosourea streptozotocin (STZ) were evaluated in DNA repair-deficient E. coli mutants. Strains not proficient in recombinational repair which lack either RecA protein or RecBC gene products were highly sensitive to STZ. In contrast, cells that constitutively synthesize RecA protein and cannot initiate SOS repair mechanisms because of uncleavable LexA repressor (recAo98 lexA3) were resistant to this drug compared to a lexA3 strain. Further, E. coli cells lacking both 3-methyladenine DNA glycosylases I (tag) and II (alkA) also were highly sensitive to STZ. DNA synthesis was most inhibited by STZ in recA and alkA tag E. coli mutants, but was suppressed less markedly in wild-type and recBC cells. DNA degradation was most extensive in recA E. coli after STZ treatment, while comparable in recBC, alkA tag, and wild-type cells. Although increased single-stranded DNA breaks were present after STZ treatment in recA and recBC mutants compared to the wild type, no significant increase in DNA single-stranded breaks was noted in alkA tag E. coli. Further, DNA breaks in recBC cells were repaired, while those present in recA cells were not. These findings establish the critical importance of both recombinational repair and 3-methyladenine DNA glycosylase in ameliorating cytotoxic effects and DNA damage caused by STZ in E. coli.


Mutation Research | 1988

Gene expression in E. coli after treatment with streptozotocin

Robert J. Fram; Martin G. Marinus; Michael R. Volkert

Gene induction by the methylating agents streptozotocin (STZ), N-methyl-N-nitrosourea (MNU), and N-methyl-N-nitro-N-nitrosoguanidine (MNNG) was evaluated in E. coli fusion mutants. These mutants have fusions of the lac operon to genes induced by treatment with sublethal levels of alkylating agents and were previously selected from random insertions of the Mu-dl (Apr lac) phage by screening for induction of beta-galactosidase activity in the presence of methyl methanesulfonate or MNNG. The results demonstrate that STZ differs from MNNG and MNU in failing to induce aidC expression. Further, expression of aidC after exposure to MNU and MNNG occurs only in nonaerated cultures; aeration blocks the induction. Induction of aidD, alkA, aidB, and sfiA expression occurs with all 3 agents although at markedly lower concentrations of MNNG and STZ compared to MNU. alkA and to a lesser extent aidD mutants of E. coli strains were more sensitive to these agents, while no differences were evident between wild-type and aidB or aidC fusion mutants.


Cell Biology and Toxicology | 1986

A COMPARISON OF THE EFFECTS OF CYTOSINE ARABINOSIDE AND BETA-LACTAMS ON DNA SYNTHESIS AND CELLULAR PROLIFERATION

Robert J. Fram

Mechanisms underlying the inhibition of DNA synthesis are extensively reviewed elsewhere (Fram and Kufe, 1986; Kufe and Major, 1982). After transport across the cell membrane, ara-C is phosphorylated to the 5-monophosphate by deoxycytidine kinase (Plagemann, 1978). Ara-CMP is then sequentially phosphorylated to ara-CTP by pyrimidine nucleoside monophosphate kinase and nucleoside diphosphokinase. While prior studies emphasized the competitive inhibition of polymerase alpha by ara-CTP as a means of inhibiting replicative DNA synthesis (Momparler et al., 1968; Furth and Cohen, 1968; Graham and Whitmore, 1970 a,b), kinetic studies have demonstrated that ara-CTP is a weak competitive inhibitor of this enzyme and that this competition does not completely explain the effect of this agent on DNA synthesis (Momparler, 1982). Other reports have demonstrated that ara-C is incorporated in internucleotide linkage (Momparler, 1969) as well as at the chain terminus (Graham and Whitmore, 1970a). These studies, however, did not correlate the extent of incorporation with either inhibition of DNA synthesis or cytotoxic effects.


Biochemical Pharmacology | 1990

Mechanisms underlying resistance to streptozotocin in Mer+ and Mer− human tumor lines

Robert J. Fram; Norman Robichaud

Streptozotocin (STZ) is a monofunctional nitrosourea employed in the treatment of patients with islet cell tumors. To analyze the role of DNA repair mechanisms in causing resistance to STZ, we evaluated the cytotoxicity by this agent in three human tumor lines that differ with respect to their abilities to repair N-methyl-N-nitro-N-nitrosoguanidine (MNNG) damaged virus (the Mer phenotype). HT-29, A2182, and BE human tumor lines are high, intermediate and low, respectively, with regard to features that define the Mer phenotype. Our results demonstrated that the order of resistance to STZ is HT-29 greater than A2182 greater than BE. The degree of inhibition of DNA synthesis by STZ was in the following order: BE greater than A2182 greater than HT-29. O6-Alkyltransferase activity was increased markedly in HT-29 cells compared to A2182 cells which, in turn, had significantly increased levels compared to the BE line. Other potential factors such as 3-methyladenine DNA glycosylase activity, the induction by STZ of single-stranded DNA breaks, and the kinetics of repair of these breaks do not clearly underlie differences in cytotoxicity among the three tumor lines. However, increased topoisomerase II activity, as well as enhanced sensitivity to agents that interact with topoisomerase II, was present in A2182 cells compared to BE cells. These findings demonstrate that while O6-alkyltransferase contributes to resistance to STZ in some Mer+ tumor lines, other mechanisms may also contribute to resistance to this agent.


Molecular Pharmacology | 1985

Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage.

Robert J. Fram; Paul S. Cusick; John M. Wilson; Martin G. Marinus


Cancer Research | 1990

Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells

Robert J. Fram; Bruce A. Woda; John M. Wilson; Norman Robichaud

Collaboration


Dive into the Robert J. Fram's collaboration.

Top Co-Authors

Avatar

Martin G. Marinus

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Norman Robichaud

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Michael R. Volkert

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Paul S. Cusick

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Alan Lipton

Penn State Milton S. Hershey Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruce A. Woda

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Donna J. Glover

Hospital of the University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

J. Sullivan

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

M. George

University of Massachusetts Medical School

View shared research outputs
Researchain Logo
Decentralizing Knowledge